This hybrid event will highlight research and innovation related to the discovery of the BRCA1 and BRCA2 genes, including the work of Dr. Steven Narod, Senior Scientist at Women’s College Hospital Research and Innovation Institute, who contributed to their discovery. The event will showcase the progress our team has made since the discovery of these genes.
We are pleased to welcome guests both:
In-person at Women’s College Hospital in Toronto
Online via Zoom.
DAY 1: NOV. 4, 2024
RESEARCHERS & HEALTH PROFESSIONALS:
- Doors Open: 8:30 a.m.
- Program Begins: 9:00 a.m.
- Closing Reception: 3:45 p.m.
DAY 2: NOV. 5, 2024
PATIENTS & THE PUBLIC
- Doors Open: 9:30 a.m.
- Program Begins: 10:00 a.m.
- Closing Reception: 3:00 p.m.
WHO SHOULD ATTEND THIS HYBRID EVENT
DAY 1: Physicians and other healthcare providers, genetic counsellors, researchers and other professionals working in the prevention, detection and treatment of breast and ovarian cancers associated with mutations in the BRCA1 or BRCA2 genes.
DAY 2: Any members of the public or patients who carry, or have family members who carry, a mutation in the BRCA1 or BRCA2 genes or other genes associated with an increased risk of breast or ovarian cancer.
WHY ATTEND
Dr. Steven Narod, Senior Scientist at Women’s College Hospital Research and Innovation Institute, was part of the team that made this important medical breakthrough. He and the Hereditary Cancer Research Unit at Women’s College Hospital have continued to make significant impacts on the management of individuals at high-risk of developing breast and ovarian cancers.
At this event, we will highlight findings from 30 years of research and innovation, including:
- establishing the effectiveness of cancer risk reduction surgeries
- treatment of BRCA-associated breast cancer
- contributions to national and international guidelines that inform care across the globe
- and much more
A light meal and refreshments will be served to in-person attendees.
REGISTRATION FEE: $25 (in-person) or $15 (virtual)
Please note: Tickets are non-refundable
This event is hosted by The Peter Gilgan Centre for Women’s Cancers at Women’s College Hospital with support from AstraZeneca and Merck. The receptions are hosted by Women’s College Hospital Foundation.